Skip to main content

Articles

Page 12 of 39

  1. P-type ATPase inhibitors are among the most successful and widely prescribed therapeutics in modern pharmacology. Clinical transition has been safely achieved for H+/K+ ATPase inhibitors such as omeprazole and Na

    Authors: Luca Pagliaro, Matteo Marchesini and Giovanni Roti
    Citation: Journal of Hematology & Oncology 2021 14:8
    Content type: Review Published on:

  2. Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activat...

    Authors: Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright and Jennifer Wu
    Citation: Journal of Hematology & Oncology 2021 14:7
    Content type: Review Published on:

  3. HOMER family scaffolding proteins (HOMER1-3) play critical roles in the development and progression of human disease by regulating the assembly of signal transduction complexes in response to extrinsic stimuli...

    Authors: Qinghua Liu, Lixin He, Siqi Li, Fengyan Li, Guangzheng Deng, Xinjian Huang, Muwen Yang, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Jinxin Chen, Xuxia Wu, Xi Wang, Libing Song and Chuyong Lin
    Citation: Journal of Hematology & Oncology 2021 14:6
    Content type: Research Published on:

  4. Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

    Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe
    Citation: Journal of Hematology & Oncology 2021 14:5
    Content type: Review Published on:

  5. Prior chemotherapy and/or underlying morbidity commonly leads to poor mobilisation of hematopoietic stem cells (HSC) for transplantation in cancer patients. Increasing the number of available HSC prior to mobi...

    Authors: Simranpreet Kaur, Anuj Sehgal, Andy C. Wu, Susan M. Millard, Lena Batoon, Cheyenne J. Sandrock, Michelle Ferrari-Cestari, Jean-Pierre Levesque, David A. Hume, Liza J. Raggatt and Allison R. Pettit
    Citation: Journal of Hematology & Oncology 2021 14:3
    Content type: Research Published on:

  7. BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the pro...

    Authors: Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li and Qiming Wang
    Citation: Journal of Hematology & Oncology 2021 14:1
    Content type: Review Published on:

  8. T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. ...

    Authors: Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak and Grzegorz K. Przybylski
    Citation: Journal of Hematology & Oncology 2020 13:176
    Content type: Review Published on:

  9. As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...

    Authors: Liang Wang, Lin-rong Li and Ken H. Young
    Citation: Journal of Hematology & Oncology 2020 13:175
    Content type: Review Published on:

  10. Immunotherapy has been a new standard for recurrent/metastatic head and neck cancers (R/M HNC). One of the prominent characteristics of cancer immunotherapy is the induction of immune memory followed by endure...

    Authors: Gaili Chen, Qiuji Wu, Huangang Jiang, Zheng Li, Xinying Hua, Xiaoyan Hu, Haijun Yu, Conghua Xie and Yahua Zhong
    Citation: Journal of Hematology & Oncology 2020 13:174
    Content type: Letter to the Editor Published on:

  11. Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid ...

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers
    Citation: Journal of Hematology & Oncology 2020 13:173
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:31

  13. Hematopoietic reprogramming holds great promise for generating functional target cells and provides new angle for understanding hematopoiesis. We reported before for the first time that diverse differentiated ...

    Authors: Yi Zhou, Chuijin Wei, Shumin Xiong, Liaoliao Dong, Zhu Chen, Sai-Juan Chen and Lin Cheng
    Citation: Journal of Hematology & Oncology 2020 13:171
    Content type: Letter to the Editor Published on:

  14. Proteomic characterization of cancers is essential for a comprehensive understanding of key molecular aberrations. However, proteomic profiling of a large cohort of cancer tissues is often limited by the conve...

    Authors: Yangying Zhou, T. Mamie Lih, Jianbo Pan, Naseruddin Höti, Mingming Dong, Liwei Cao, Yingwei Hu, Kyung-Cho Cho, Shao-Yung Chen, Rodrigo Vargas Eguez, Edward Gabrielson, Daniel W. Chan, Hui Zhang and Qing Kay Li
    Citation: Journal of Hematology & Oncology 2020 13:170
    Content type: Research Published on:

  15. Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired ...

    Authors: Yulong Fu, Yang Zhang, Zhe Lei, Ting Liu, Tingting Cai, Anqi Wang, Wenwen Du, Yuanyuan Zeng, Jianjie Zhu, Zeyi Liu and Jian-an Huang
    Citation: Journal of Hematology & Oncology 2020 13:169
    Content type: Research Published on:

  18. Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing to single-molecular, single-cell and s...

    Authors: Mingye Hong, Shuang Tao, Ling Zhang, Li-Ting Diao, Xuanmei Huang, Shaohui Huang, Shu-Juan Xie, Zhen-Dong Xiao and Hua Zhang
    Citation: Journal of Hematology & Oncology 2020 13:166
    Content type: Review Published on:

  19. The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investi...

    Authors: Ya Zhang and Xin Wang
    Citation: Journal of Hematology & Oncology 2020 13:165
    Content type: Review Published on:

  20. B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determi...

    Authors: Gils Roex, Marijke Timmers, Kristien Wouters, Diana Campillo-Davo, Donovan Flumens, Wilfried Schroyens, Yiwei Chu, Zwi N. Berneman, Eva Lion, Feifei Luo and Sébastien Anguille
    Citation: Journal of Hematology & Oncology 2020 13:164
    Content type: Research Published on:

  22. Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative ...

    Authors: Sangeetha Venugopal and John Mascarenhas
    Citation: Journal of Hematology & Oncology 2020 13:162
    Content type: Review Published on:

  24. Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47–SIRPα interaction synergizes...

    Authors: Tracy C. Kuo, Amy Chen, Ons Harrabi, Jonathan T. Sockolosky, Anli Zhang, Emma Sangalang, Laura V. Doyle, Steven E. Kauder, Danielle Fontaine, Sangeetha Bollini, Bora Han, Yang-Xin Fu, Janet Sim, Jaume Pons and Hong I. Wan
    Citation: Journal of Hematology & Oncology 2020 13:160
    Content type: Research Published on:

  26. Chemoresistance remains a major treatment obstacle in multiple myeloma (MM). Novel new therapies are thus in need. Transient Receptor Potential Vanilloid type 1 (TRPV1) is a calcium-permeable ion channel that ...

    Authors: Katia Beider, Evgenia Rosenberg, Valeria Dimenshtein-Voevoda, Yaarit Sirovsky, Julia Vladimirsky, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Zohar Bromberg, Lola Weiss, Amnon Peled and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2020 13:158
    Content type: Research Published on:

  28. Mounting evidence has demonstrated the vital importance of tumor-associated macrophages (TAMs) and exosomes in the formation of the premetastatic niche. However, the molecular mechanisms by which tumor-derived...

    Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li
    Citation: Journal of Hematology & Oncology 2020 13:156
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:33

  30. As the most important component of the stromal cell population in the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) are crucial players in tumor initiation and progression. The interaction...

    Authors: Zengli Fang, Jin Xu, Bo Zhang, Wei Wang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2020 13:154
    Content type: Review Published on:

  31. The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of eff...

    Authors: Li Zhang, Lin Tian, Xiaoyang Dai, Hua Yu, Jiajia Wang, Anhua Lei, Mengmeng Zhu, Jianpo Xu, Wei Zhao, Yuqing Zhu, Zhen Sun, Hao Zhang, Yongxian Hu, Yanlin Wang, Yuming Xu, George M. Church…
    Citation: Journal of Hematology & Oncology 2020 13:153
    Content type: Letter to the Editor Published on:

  32. Exosomes are a subset of extracellular vesicles that carry specific combinations of proteins, nucleic acids, metabolites, and lipids. Mounting evidence suggests that exosomes participate in intercellular commu...

    Authors: Le Zhu, Hao-Ting Sun, Shun Wang, Sheng-Lin Huang, Yan Zheng, Chao-Qun Wang, Bei-Yuan Hu, Wei Qin, Tian-Tian Zou, Yan Fu, Xiao-Tian Shen, Wen-Wei Zhu, Yan Geng, Lu Lu, Hu-liang Jia, Lun-Xiu Qin…
    Citation: Journal of Hematology & Oncology 2020 13:152
    Content type: Review Published on:

  33. Immunosenescence is a process of immune dysfunction that occurs with age and includes remodeling of lymphoid organs, leading to changes in the immune function of the elderly, which is closely related to the de...

    Authors: Jingyao Lian, Ying Yue, Weina Yu and Yi Zhang
    Citation: Journal of Hematology & Oncology 2020 13:151
    Content type: Review Published on:

  34. The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplant...

    Authors: Yang Yang, Yi Li, Huiyao Gu, Mengmeng Dong and Zhen Cai
    Citation: Journal of Hematology & Oncology 2020 13:150
    Content type: Review Published on:

  35. Pyroptosis is a form of proinflammatory gasdermin-mediated programmed cell death. Abnormal mucosal inflammation in the intestine is a critical risk factor for colitis-associated colorectal cancer (CAC). Howeve...

    Authors: Gao Tan, Chongyang Huang, Jiaye Chen and Fachao Zhi
    Citation: Journal of Hematology & Oncology 2020 13:149
    Content type: Rapid communication Published on:

  36. The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL pat...

    Authors: Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh…
    Citation: Journal of Hematology & Oncology 2020 13:148
    Content type: Letter to the Editor Published on:

  37. Oncological care was largely derailed due to the reprioritisation of health care services to handle the initial surge of COVID-19 patients adequately. Cancer screening programmes were no exception in this repr...

    Authors: Avinash G. Dinmohamed, Matteo Cellamare, Otto Visser, Linda de Munck, Marloes A. G. Elferink, Pieter J. Westenend, Jelle Wesseling, Mireille J. M. Broeders, Ernst J. Kuipers, Matthias A. W. Merkx, Iris D. Nagtegaal and Sabine Siesling
    Citation: Journal of Hematology & Oncology 2020 13:147
    Content type: Letter to the Editor Published on:

  38. The epidemiology of esophageal cancer (EC) can elucidate its causes and risk factors and help develop prevention strategies. We aimed to provide an overview of the burden, trends, and risk factors of EC in Chi...

    Authors: Si Yang, Shuai Lin, Na Li, Yujiao Deng, Meng Wang, Dong Xiang, Grace Xiang, Shuqian Wang, Xianghua Ye, Yi Zheng, Jia Yao, Zhen Zhai, Ying Wu, Jingjing Hu, Huafeng Kang and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2020 13:146
    Content type: Research Published on:

  39. Drug-loaded nanoparticles have established their benefits in the fight against multiple myeloma; however, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufficient effica...

    Authors: David T. Omstead, Franklin Mejia, Jenna Sjoerdsma, Baksun Kim, Jaeho Shin, Sabrina Khan, Junmin Wu, Tanyel Kiziltepe, Laurie E. Littlepage and Basar Bilgicer
    Citation: Journal of Hematology & Oncology 2020 13:145
    Content type: Research Published on:

  40. Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-rib...

    Authors: Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong and Tian Zhang
    Citation: Journal of Hematology & Oncology 2020 13:144
    Content type: Review Published on:

  42. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13045-020-00969-0.

    Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao- Rong Dong
    Citation: Journal of Hematology & Oncology 2020 13:142
    Content type: Retraction Note Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:125

  43. Glioblastoma (GBM) is a universally lethal tumor with frequently overexpressed or mutated epidermal growth factor receptor (EGFR). NADPH quinone oxidoreductase 1 (NQO1) and glutathione-S-transferase Pi 1 (GSTP...

    Authors: Kecheng Lei, Xiaoxia Gu, Alvaro G. Alvarado, Yuhong Du, Shilin Luo, Eun Hee Ahn, Seong Su Kang, Bing Ji, Xia Liu, Hui Mao, Haian Fu, Harley I. Kornblum, Lingjing Jin, Hua Li and Keqiang Ye
    Citation: Journal of Hematology & Oncology 2020 13:141
    Content type: Research Published on:

  44. IKZF1 belongs to the IKAROS family of transcription factors, and its deletion/mutation frequently affects acute lymphoblastic leukemia. In acute myeloid leukemia, IKZF1 deletion has been demonstrated recurrent, b...

    Authors: Xiang Zhang, Xuewu Zhang, Xia Li, Yunfei Lv, Yanan Zhu, Jinghan Wang, Jie Jin and Wenjuan Yu
    Citation: Journal of Hematology & Oncology 2020 13:140
    Content type: Letter to the Editor Published on:

  45. Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (

    Authors: Lindsey T. Brinton, Pu Zhang, Katie Williams, Daniel Canfield, Shelley Orwick, Steven Sher, Ronni Wasmuth, Larry Beaver, Casey Cempre, Jordan Skinner, Matthew Cannon, Mukul Govande, Bonnie Harrington, Amy Lehman, John C. Byrd, Rosa Lapalombella…
    Citation: Journal of Hematology & Oncology 2020 13:139
    Content type: Rapid communication Published on:

  47. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and child...

    Authors: Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti and Eunice S. Wang
    Citation: Journal of Hematology & Oncology 2020 13:137
    Content type: Review Published on:

  48. Cancer stem cells (CSCs) represent a tumor subpopulation responsible for tumor metastasis and resistance to chemo- and radiotherapy, ultimately leading to tumor relapse. As a consequence, the detection and era...

    Authors: Julia López de Andrés, Carmen Griñán-Lisón, Gema Jiménez and Juan Antonio Marchal
    Citation: Journal of Hematology & Oncology 2020 13:136
    Content type: Review Published on:

  49. Pediatric myelodysplastic syndrome (PMDS) is a very rare and still poorly characterized disorder. In this work, we identified novel potential targets of PMDS by determining genes with aberrant expression, whic...

    Authors: Lorena Zubovic, Silvano Piazza, Toma Tebaldi, Luca Cozzuto, Giuliana Palazzo, Viktoryia Sidarovich, Veronica De Sanctis, Roberto Bertorelli, Tim Lammens, Mattias Hofmans, Barbara De Moerloose, Julia Ponomarenko, Martina Pigazzi, Riccardo Masetti, Cristina Mecucci, Giuseppe Basso…
    Citation: Journal of Hematology & Oncology 2020 13:135
    Content type: Letter to the Editor Published on:

  50. High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-...

    Authors: Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q. Bernardini and Thomas Kislinger
    Citation: Journal of Hematology & Oncology 2020 13:134
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us